Key points for investors:
- FY25 financials: Record sales of $1.9bn (revenue +13.5% YoY), EBITDA +17%, NPAT and EPS +21%; strong cash conversion (95% operating cash conversion) and closing net cash of ~$1.06bn. Dividend: ordinary FY25 dividends declared totalling $0.20/share (payout ~71%); Board intends to declare a $300m special dividend (subject to conditions). Ordinary dividend policy reaffirmed at 60–80% of normalised NPAT.
- China performance and market position: a2 reached #4 overall in China IMF with 8% market share; English-label IMF was the standout, up 17% (CBEC and O2O strength); China-label up 3.3% with record market share despite a declining market. Company is focused on capturing further growth in lower-tier cities and converging China-label and English-label strategies.
- Supply-chain transformation (major strategic change): announced two linked transactions: acquisition of Yashili New Zealand (a2 Pokeno) for NZD $282m (debt & cash-free) — facility already produces 2 English-label products and holds 2 China-label registrations (with scope for a third) — plus a multiyear ~$100m CapEx program to upgrade capacity/capability; and divestment of a2’s 75% stake in MVM (to Open Country) expected to yield net proceeds ~ $100m (deemed a non-cash loss on sale of ~ $130m in H1 FY26). Rationale: faster China-label market access, vertical margin capture (insourcing a2 Platinum volumes), expanded China-label portfolio, and optimized asset footprint.
- Financial impact and outlook: combined transactions modeled to deliver IRR > cost of capital; ROIC expected to hit cost of capital by FY29. Net investment (purchase price + CapEx + working capital less MVM proceeds) is presented ~ $400m. Pokeno is expected to be loss-making in FY26 (company states ~$30–35m EBITDA loss in FY26 including $10–15m transformation costs), approx EBITDA breakeven in FY27, with profitability thereafter as insourcing and scale occur. FY26 continuing-operations outlook (assuming transactions complete): revenue growth - high single-digit vs FY25 continuing ops; EBITDA margin ~15–16%; NPAT similar to FY25 reported (~$203m). FY30 aspiration: incremental China-label sales >$100m and China-label EBITDA margins >= ~26% for the new portfolio slots (company-level estimates provided as guidance rather than precise line items).
- Capital management: Board intends a $300m special dividend (unimputed and fully franked), conditional on regulatory approvals (amendment of China registrations) and completion of MVM sale; ordinary dividend policy retained. Pro forma cash and announced returns leave the company with headroom but also a more capital-intensive path while Pokeno is scaled.
- Operational/sustainability highlights: MVM plant converted to 100% certified renewable energy for boiler operations; Scope 3 emission intensity reduced ~1/3 vs 2021 baseline; packaging progress and participation in AgriZero and on-farm sustainability projects; ongoing focus on R&D and innovation (Genesis plus other launches).
- Key risks and execution considerations: regulatory approvals in China (SAMR/GACC amendment timelines up to ~12 months), integration/execution risk in moving manufacturing and insourcing a2 Platinum from Synlait, supply continuity with Synlait during transition, initial Pokeno losses and transition costs, and market/channel mix shifts between English-label and China-label that could affect near-term margins. Management emphasizes a multiyear, staged execution plan and that outcomes are conditional on approvals and successful integration.
Sign In
Buy ACOPF
